shutterstock_1803358558_rafapress
rafapress / Shutterstock.com
10 December 2020AmericasRory O'Neill

Tris blocks Actavis’ ADHD generic

New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder (ADHD) drug Quillivant XR (methylphenidate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 January 2026   Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.
Americas
22 January 2026   A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.
Americas
22 January 2026   From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.